10-Q: Sangamo Faces Going Concern Doubt, Nasdaq Delisting Threat

Sangamo Therapeutics reported a significant revenue decline and increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern, while also receiving a Nasdaq delisting extension.

Summary

• Reported a net loss of $34.9 million for the three months ended September 30, 2025, compared to a net income of $10.7 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $85.5 million, an increase from $74.5 million in 2024.
• Revenues significantly decreased by 98.8% to $0.6 million for the three months ended September 30, 2025, and by 50% to $25.3 million for the nine months ended September 30, 2025, primarily due to lower collaboration revenue from Genentech and the termination of the Pfizer agreement.
• Cash and cash equivalents stood at $29.6 million as of September 30, 2025, with management estimating these funds, plus recent capital raises, will only be sufficient into the first quarter of 2026.
• Management has raised substantial doubt about the company's ability to continue as a going concern.
• Received a 180-day extension from Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement.
• Advanced its Fabry disease program (isaralgagene civaparvovec) with positive Phase 1/2 STAAR study data and anticipates a Biologics License Application (BLA) submission as early as Q1 2026, but has been unsuccessful in securing a commercialization partner to date.
• Progressed preclinical neurology programs, with ST-503 (small fiber neuropathy) expecting first patient dosing in coming months and ST-506 (prion disease) expecting a Clinical Trial Application (CTA) submission as early as mid-2026.

Sentiment

Score: 2

Explanation: The filing presents a highly negative financial outlook, explicitly stating 'substantial doubt' about the company's ability to continue as a going concern. This is compounded by a dramatic revenue decline, increased net losses, and a Nasdaq delisting threat. While there are some positive clinical updates and new collaborations, the severe liquidity crisis and the explicit mention of exploring bankruptcy protection overshadow these developments, indicating a very high level of financial distress and operational risk.

Positives

• Received an $18.0 million upfront license payment from Eli Lilly and Company in April 2025 for a global capsid delivery license agreement, with eligibility for up to $1.4 billion in additional fees and milestones.
• Received a $6.0 million payment from Pfizer in October 2025 for the exercise of a buyout option for a license to certain zinc finger modified cell lines.
• Positive clinical data from the Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920) in Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks and 1.747 mL/min/1.73m2/year at Week 104.
• Demonstrated durability of effect in the Fabry study with elevated alpha-galactosidase A activity maintained for up to 4.5 years.
• FDA reiterated agreement on eGFR slope as an endpoint for an accelerated approval pathway for isaralgagene civaparvovec and agreed on the adequacy of the safety package for BLA submission.
• Progress in preclinical neurology programs, including patient enrollment commencement for the Phase 1/2 STAND study of ST-503 for small fiber neuropathy and advancing CTA-enabling activities for ST-506 for prion disease.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, with current cash and equivalents, plus recent capital raises, only sufficient into Q1 2026.
• Net loss increased to $85.5 million for the nine months ended September 30, 2025, from $74.5 million in the prior year period.
• Total revenues decreased by 98.8% to $0.6 million for the three months ended September 30, 2025, and by 50% to $25.3 million for the nine months ended September 30, 2025, primarily due to the absence of significant collaboration revenue from Genentech in 2025 and the termination of the Pfizer collaboration.
• Received a Nasdaq Extension Notice for failing to meet the $1.00 minimum bid price requirement, with a deadline of April 27, 2026, to regain compliance.
• Unsuccessful in consummating a commercialization agreement for the Fabry disease program to date, which could substantially impair the ability to raise additional capital.
• The collaboration agreement with Pfizer for hemophilia A was terminated effective April 21, 2025, resulting in no further milestone payments or royalties from Pfizer for that program.
• Total stockholders' equity significantly decreased to $6.2 million as of September 30, 2025, from $22.8 million as of December 31, 2024.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant operating losses, negative cash flows, and limited liquidity, requiring substantial additional funding.
• Inability to secure collaboration partners for programs, particularly a commercialization partner for the Fabry disease program, which would substantially impair the ability to raise additional capital.
• Future sales and issuances of equity securities would result in substantial dilution to stockholders.
• No approved products or product revenues, with success dependent on preclinical and clinical trial results demonstrating safety and efficacy, which is expensive, lengthy, challenging, and unpredictable.
• Core preclinical neurology programs are in early stages, with potential difficulties in advancing product candidates to clinical development.
• Success in early-stage trials may not be indicative of later-stage results, and preliminary data may differ from final data.
• Disruptions at the FDA (e.g., workforce reduction, inadequate funding) could prevent normal functions, negatively impacting business and regulatory approvals.
• Highly competitive biotechnology and genomic medicine businesses, with rivals potentially developing superior or faster-commercialized products.
• Complex, expensive, highly regulated, and risky manufacture, storage, and transport of product candidates.
• Even with successful development and regulatory approval, products may not gain market acceptance.
• Difficult, time-consuming, and costly to obtain, maintain, and enforce patent protections, with risks of infringement lawsuits.
• Difficulties in hiring, integrating, and retaining qualified skilled employees.
• Unfavorable global economic conditions could negatively impact operations and ability to operate as a going concern.
• Failure to regain compliance with Nasdaq Capital Market listing standards could lead to delisting, adversely affecting liquidity and stock price, and impairing capital raising ability.
• Stock price volatility and potential class action securities litigation.
• Potential for significant additional impairment charges on long-lived assets.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, increasing R&D expenses and supply chain complexity.
• FDA discontinuing its Accelerated Approval program or making it unavailable for isaralgagene civaparvovec would materially and adversely affect the ability to secure a collaboration partner and obtain timely approval.

Future Outlook

The company estimates its current cash and cash equivalents, combined with recent capital raises, will only be sufficient to meet liquidity requirements into the first quarter of 2026. Substantial additional funding is required to execute the operating plan and continue as a going concern. The company expects research and development expenses to increase in the near-term due to Fabry disease program BLA readiness activities and anticipates further increases in the next several years if substantial additional capital is successfully raised to advance its pipeline. A Biologics License Application (BLA) submission for the Fabry disease program is anticipated as early as Q1 2026, and a Clinical Trial Application (CTA) submission for the prion disease program (ST-506) is expected as early as mid-2026. The company continues to actively seek additional capital through strategic collaborations, equity or debt financing, and other sources, particularly a commercialization partner for its Fabry disease program.

Management Comments

• "Substantial doubt about our ability to continue to operate as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued."
• "Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors."
• "We are engaged in business development discussions with potential counterparties concerning a commercialization agreement for our Fabry disease program, but have been unsuccessful in consummating any such transaction to date."
• "If adequate funds are not available to us on a timely basis, or at all, we will be required to take significant additional actions to address our liquidity needs, including substantial additional cost reduction measures... or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code."
• "We have explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders."

Industry Context

The company operates in a highly competitive biotechnology and genomic medicine industry, focusing on neurology. Its reliance on collaborations for funding and program advancement is a common strategy in the sector, but the termination of key partnerships and the challenge of securing new ones highlight the inherent risks. The macroeconomic environment, including financial instability and regulatory disruptions at agencies like the FDA, poses additional challenges, reflecting broader industry headwinds for emerging biotechnology companies, particularly those with early-stage pipelines and significant capital needs.

Management Changes

Corporate Governance

Legal Proceedings

• Not party to any material pending legal proceedings.

Stakeholder Impact

• Shareholders: Significant dilution from recent and potential future equity offerings, substantial risk of losing all or part of investment due to going concern doubt, potential delisting from Nasdaq, and stock price volatility.
• Employees: Ongoing impact from past restructurings (France, November 2023), potential for further workforce reductions if additional funding is not secured, and uncertainty regarding job security.
• Customers/Partners: Termination of Pfizer collaboration, potential for new collaborations (Lilly, Astellas, Genentech) to provide future revenue, but also risk of partners withdrawing if company's financial stability deteriorates further.
• Creditors: Increased risk due to substantial doubt about going concern and limited liquidity, potentially impacting ability to meet future financial obligations.

Next Steps

• Dose the first patient in the Phase 1/2 STAND study for ST-503 (small fiber neuropathy) in the coming months.
• Prepare for an anticipated Biologics License Application (BLA) submission for isaralgagene civaparvovec (Fabry disease) as early as Q1 2026.
• Continue business development discussions for a potential Fabry commercialization agreement.
• Advance Clinical Trial Application (CTA) enabling activities for ST-506 (prion disease), with submission expected as early as mid-2026.
• Actively seek substantial additional capital through collaborations, equity/debt financing, or other sources to fund operations and R&D.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by April 27, 2026.
• Complete the November 2023 Restructuring in the near future.
• Replenish or replace the $1.5 million letter of credit for the Brisbane, California facility lease by December 31, 2026.
• Pay the deferred base rent of $5.06 million for the Brisbane facility by January 5, 2027.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt' about the company's ability to continue as a going concern, with current cash only sufficient into Q1 2026. This severe liquidity crisis is exacerbated by a dramatic 98.8% year-over-year revenue decline in Q3 2025 and increased net losses. The company also faces a Nasdaq delisting threat due to its low share price. While there are some positive clinical developments for the Fabry program and new collaborations, these are overshadowed by the immediate and existential financial risks, including the explicit mention of exploring bankruptcy protection. The inability to secure a commercialization partner for the Fabry program further impairs capital raising efforts. Given the high probability of significant further dilution, potential delisting, and the risk of ceasing operations, the stock presents an extremely high-risk profile with a strong likelihood of further value erosion.

Keywords

Genomic Medicine, Neurology, Gene Therapy, Gene Editing, Zinc Finger, Fabry Disease, STAC-BBB, Preclinical Development, Clinical Trials, Biologics License Application, FDA Accelerated Approval, Going Concern, Nasdaq Delisting, Biotechnology, Rare Disease, Small Fiber Neuropathy, Prion Disease, Capital Raise, Collaboration Agreements